Инклисиран – новая эра в гиполипидемической терапии

Инклисиран – новый гиполипидемический препарат, ингибирующий синтез белка PCSK9 с помощью процесса, называемого «РНК-интерференция», и представляющий собой двухцепочечную модифицированную РНК, связанную с углеводной молекулой N-ацетилгалактозамина (GalNAc) – лигандом асиалогликопротеинового рецептора, экспрессирующегося гепатоцитами. Попадая в гепатоциты, инклисиран вызывает расщепление матричной РНК и соответствующее снижение синтеза белка PCSK9. В свою очередь это приводит к усилению захвата циркулирующих липопротеидов низкой плотности (ЛНП) специфическими рецепторами гепатоцитов и соответственно к снижению их концентрации в крови. Эффективность и безопасность применения инклисирана для снижения концентрации холестерина (ХС) ЛНП в крови и влияния на риск развития кинических осложнений атеросклероза были изучены и изучаются в рамках программы ORION, включающей большое число клинических исследований. По результатам выполнения программы в настоящее время показано, что инклисиран эффективно снижает уровень ХС ЛНП и частоту развития сердечно-сосудистых осложнений в отсутствие клинически значимых неблагоприятных реакций. Важным преимуществом инклисирана по сравнению с другими липидснижающими препаратами является режим его введения – 2 раза в год, позволяющий значительно повысить приверженность пациентов к лечению и эффективность гиполипидемической терапии.

1. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670–81. DOI: 10.1016/S0140-6736(10)61350-5

2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455

3. Waters DD, Brotons C, Chiang C-W, Ferrières J, Foody J, Jukema JW et al. Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals. Circulation. 2009;120(1):28–34. DOI: 10.1161/CIRCULATIONAHA.108.838466

4. Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statintreated patients. Atherosclerosis. 2016;255:200–9. DOI: 10.1016/j.atherosclerosis.2016.09.004

5. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M et al. Discontinuation of Statins in Routine Care Settings: A Cohort Study. Annals of Internal Medicine. 2013;158(7):526–34. DOI: 10.7326/0003-4819-158-7-201304020-00004

6. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine. 2006;354(12):1264–72. DOI: 10.1056/NEJMoa054013

7. Banach M, Rizzo M, Obradovic M, Montalto G, Rysz J, Mikhailidis DP et al. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders? Current Pharmaceutical Design. 2013;19(21):3869–77. DOI: 10.2174/13816128113199990303

8. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology. 2017;9(2):76–91. DOI: 10.4330/wjc.v9.i2.76

9. Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R et al. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation. 2017;135(4):338–51. DOI: 10.1161/CIRCULATIONAHA.116.025080

10. Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R et al. Effects of PCSK9 Inhibition with Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2017;135(4):352–62. DOI: 10.1161/CIRCULATIONAHA.116.025253

11. Karagiannis AD, Liu M, Toth PP, Zhao S, Agrawal DK, Libby P et al. Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. Current Atherosclerosis Reports. 2018;20(4):20. DOI: 10.1007/s11883-018-0718-x

12. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science. 2015;11(1):1–23. DOI: 10.5114/aoms.2015.49807

13. Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G et al. The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology. 2018;72(1):96–118. DOI: 10.1016/j.jacc.2018.04.040

14. Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Atherosclerosis. 2016;248:62–75. DOI: 10.1016/j.atherosclerosis.2016.02.018

15. Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nature Reviews Genetics. 2015;16(9):543–52. DOI: 10.1038/nrg3978

16. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–55. DOI: 10.1016/j.cell.2009.01.035

17. Bernards R. Exploring the Uses of RNAi – Gene Knockdown and the Nobel Prize. New England Journal of Medicine. 2006;355(23):2391–3. DOI: 10.1056/NEJMp068242

18. Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature. 2009;457(7228):396–404. DOI: 10.1038/nature07754

19. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song J-J et al. Argonaute2 Is the Catalytic Engine of Mammalian RNAi. Science. 2004;305(5689):1437–41. DOI: 10.1126/science.1102513

20. Meister G. Argonaute proteins: functional insights and emerging roles. Nature Reviews Genetics. 2013;14(7):447–59. DOI: 10.1038/nrg3462

21. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. Activation of the interferon system by short-interfering RNAs. Nature Cell Biology. 2003;5(9):834–9. DOI: 10.1038/ncb1038

22. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews. 2015;87: 108–19. DOI: 10.1016/j.addr.2015.01.007

23. Rand TA, Petersen S, Du F, Wang X. Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation. Cell. 2005;123(4):621–9. DOI: 10.1016/j.cell.2005.10.020

24. Huang X, Leroux J-C, Castagner B. Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor. Bioconjugate Chemistry. 2017;28(2):283–95. DOI: 10.1021/acs.bioconjchem.6b00651

25. Wang N, Tall AR. A New Approach to PCSK9 Therapeutics. Circulation Research. 2017;120(7):1063–5. DOI: 10.1161/CIRCRESAHA.117.310610

26. Cupido AJ, Kastelein JP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovascular Research (2020) 116, e136–e139; doi:10.1093/cvr/cvaa212

27. Nishikido T, Ray KK. Inclisiran for the treatment of dyslipidemia. Expert Opinion on Investigational Drugs. 2018;27(3):287–94. DOI: 10.1080/13543784.2018.1442435

28. Springer AD, Dowdy SF. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Therapeutics. 2018;28(3):109–18. DOI: 10.1089/nat.2018.0736

29. Nair JK, Willoughby JLS, Chan A, Charisse K, Alam MdR, Wang Q et al. Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. Journal of the American Chemical Society. 2014;136(49):16958–61. DOI: 10.1021/ja505986a

30. Lamb YN. Inclisiran: First Approval. Drugs. 2021;81(3):389–95. DOI: 10.1007/s40265-021-01473-6

31. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proceedings of the National Academy of Sciences. 2008;105(33):11915–20. DOI: 10.1073/pnas.0805434105

32. Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A et al. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety. 2022;21(1):9–20. DOI: 10.1080/14740338.2022.1988568

33. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020;382(16):1520–30. DOI: 10.1056/NEJMoa1913805

34. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507–19. DOI: 10.1056/NEJMoa1912387

35. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. The American Journal of Cardiology. 2020;134:69–73. DOI: 10.1016/j.amjcard.2020.08.018

36. Kallend D, Stoekenbroek R, He Y, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. Journal of Clinical Lipidology. 2022;16(2):208–19. DOI: 10.1016/j.jacl.2022.01.001

37. Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings. 2020;95(1):77–89. DOI: 10.1016/j.mayocp.2019.08.021

38. Leng G. Radical or not, NICE makes evidence based recommendations. BMJ. 2021;375:n2831. DOI: 10.1136/bmj.n2831